CoChat

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

Open access
Ahrén, Bo, Hirsch, Irl B., Pieber, Thomas R., Mathieu, Chantal, Gómez-Peralta, Fernando, Hansen, Troels Krarup, Philotheou, Areti, Birch, Sune, Christiansen, Erik, Jensen, Thomas Jon, Buse, John B., for the ADJUNCT TWO Investigators · 2016 · Diabetes Care

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin. RESULTS: Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: –0.33% [3.6 mmol/mol]; 1.2 mg: –0.22% [2.4 mmol/mol]; 0.6 mg: –0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]). Liraglutide significantly reduced mean body weight (–5.1, –4.0, and –2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (–0.2 kg). Significant reductions in daily insulin dose and increases in quality of life were seen with liraglutide versus placebo. There were higher rates of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with liraglutide 1.2 mg vs. placebo and of hyperglycemia with ketosis >1.5 mmol/L with liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01). CONCLUSIONS: In a broad population of subjects with long-standing type 1 diabetes, liraglutide added to capped insulin reduced HbA1c, body weight, and insulin requirements but with higher rates of hypoglycemia for liraglutide 1.2 mg and hyperglycemia with ketosis for liraglutide 1.8 mg.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc16-0690

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 36 references

Research works printed but not linked: 3

  1. FDA, 2005, New diabetes drug, FDA Consum, 39, 3
  2. 2013, Kidney Disease: Improving Global Outcomes. Definition and classification of CKD, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl, 3, 19
  3. Østergaard, 2015, Effects of liraglutide as add-on to insulin on counter-regulatory hormone responses, gastric emptying and glycaemic recovery during hypoglycaemia (Abstract), Diabetologia, 58, A963

Cited by

Metadata

Authors
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., Buse, J. B., & for the ADJUNCT TWO Investigators
Affiliations
  • Lund University, Lund, Sweden
  • University of Washington (US)
  • Medical University of Graz (AT)
  • KU Leuven (BE)
  • Hospital General de Segovia, Segovia, Spain
  • Aarhus University Hospital (DK)
  • University of Cape Town (ZA)
  • Novo Nordisk (Denmark) (DK)
  • University of North Carolina at Chapel Hill (US)
Venue
Diabetes Care
Published
2016-08-04
Volume
39
Issue
10
Pages
1693-1701
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2494601841
Cited by
262
References
36
Citations by year
2026: 38 · 2025: 49 · 2024: 33 · 2023: 25 · 2022: 16 · 2021: 23 · 2020: 29 · 2019: 11 · 2018: 21 · 2017: 10 · 2016: 7
FWCI
16.40
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Scopus (Elsevier) (submittedVersion)
  • UNC Libraries
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
liraglutide, type 1 diabetes, GLP-1 receptor agonists, HbA1c, glycemic control, weight loss, insulin dose reduction, hypoglycemia, diabetic ketoacidosis, quality of life
MeSH terms
Liraglutide, Adolescent, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.